Sign in

Private company

POINT Biopharma Global Inc.

Pharmaceutical preparations company1

In its 2023 annual report the company says: “POINT Biopharma Global Inc. is a next-generation radioligand company. Our platform consists of a strong pipeline of potential first-in-class and best-in-class assets, internal research and development expertise, in-house manufacturing capabilities, and a secured supply for rare medical isotopes like actinium-225 and lutetium-177. Our late-stage programs are 177 Lu-based radioligands.”49 It is headquartered in Indianapolis, Indiana.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersIndianapolis, Indiana1
  • Business address4850 West 78Th Street, Indianapolis, In 462682
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

55.4%Operating margin3
43.4%Net margin3
20.2%Return on equity3
$170.8MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development36¢$82.1M
  • Other costs7¢$14.9M
  • Income tax14¢$31.3M
  • Profit43¢$98.3M

Out of $226.6M in revenue.3

Where each dollar of operating cash went, fiscal 2022

  • Capital spending7¢$12.8M
  • Kept or used elsewhere93¢$170.8M

Out of $183.5M of cash from operations.3

Financial statements

Revenue3$226.6M in 2022
0$100.0M$200.0M$300.0M2021: $0$020212022: $226.6M$226.6M2022
Operating income43$125.5M in 2022
-$50.0M0$50.0M$100.0M$150.0M2020: -$13.1M-$13.1M20202021: -$45.5M-$45.5M2021+247%2022: $125.5M$125.5M2022
Net income43$98.3M in 2022
-$50.0M0$50.0M$100.0M2020: -$13.4M-$13.4M20202021: -$45.9M-$45.9M2021+243%2022: $98.3M$98.3M2022
Fiscal year2019202020212022
Revenue$03$226.6M3
Research and development$9.1M4$33.5M3$82.1M3
Operating expenses$45.5M3$101.1M3
Operating income-$13.1M4-$45.5M3$125.5M3
Income before tax-$45.6M3$129.6M3
Income tax$87.9K4$305.7K3$31.3M3
Net income-$13.4M4-$45.9M3$98.3M3
Earnings per share-$0.344-$0.623$1.043
Earnings per share (diluted)-$0.344-$0.623$1.023
Shares (weighted, basic)73.9M shares394.6M shares3
Shares (weighted, diluted)73.9M shares396.0M shares3

Compare POINT Biopharma Global Inc. with another company

Corporate structure

POINT Biopharma Global Inc. is part of a group headed by Eli Lilly and Company. 163 entities, 54 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of POINT Biopharma Global Inc.

  • Eli Lilly and Company Indianapolis, Indiana, United States
    • POINT Biopharma Global Inc. Indianapolis, Indiana
    • Eli Lilly (India) Subsidiary · Gurgaon, India
    • Eli Lilly (United Kingdom) Subsidiary · Basingstoke, United Kingdom
    • ImClone Systems Subsidiary
    • Lilly (China) Subsidiary · Shanghai, People's Republic of China
    • Lilly France Subsidiary · Neuilly-sur-Seine, France
    • Adverum Biotechnologies, Inc. Subsidiary · Delaware, United States
    • Adverum NC, LLC Subsidiary · Delaware, United States
    • Akouos, Inc. Subsidiary · Delaware, United States
    • Alnara Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Annapurna Therapeutics, Ltd. Subsidiary · Ireland
    • Aparito Espanya S.L. Subsidiary · Spain
    • Aparito LLC Subsidiary · Delaware, United States
    • ARMO Biosciences, Inc. Subsidiary · Delaware, United States
    • Avalanche Australia Pty Ltd. Subsidiary · Australia
    • Avid Radiopharmaceuticals, Inc. Subsidiary · Delaware, United States
    • CoLucid Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Compania Farmaceutica Eli Lilly de Centro America S.A. Subsidiary · Guatemala
    • CPD 4, Inc. Subsidiary · Delaware, United States
    • Dermira, Inc. Subsidiary · Delaware, United States
    • DICE Alpha Inc. Subsidiary · Delaware, United States
    • DICE Molecules SV, Inc. Subsidiary · Delaware, United States
    • DICE Therapeutics, Inc. Subsidiary · Delaware, United States
    • Disarm Therapeutics Inc. Subsidiary · Delaware, United States
    • Dista Ilac Ticaret Limited Sirketi Subsidiary · Turkey
    • and 138 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What POINT Biopharma Global Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$32.8M3 Dec 31, 2022$19.4M3 Dec 31, 2021+68.8%
Accumulated depreciation$1.4M3 Dec 31, 2022$03 Dec 31, 2021
Property and equipment, net$31.4M3 Dec 31, 2022$19.4M3 Dec 31, 2021+61.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$286.4M3 Dec 31, 2022$238.8M3 Dec 31, 2021+19.9%
Marketable securities, current$238.8M3 Dec 31, 2022$03 Dec 31, 2021
Marketable securities, non-current$16.1M3 Dec 31, 2022
Debt securities available for sale$254.9M3 Dec 31, 2022
Long-term investments$16.1M3 Dec 31, 2022$03 Dec 31, 2021

Leadership

Who has led POINT Biopharma Global Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Peter Kolchinsky2020–2021
  2. Joe A. McCann2021–2023

Chair

  1. Allan C. Silber2022–2023

Chief financial officer

  1. Matthew Hammond2020
  2. William L. Demers2021–2023

Chief operating officer

  1. Justyna Kelly2021–2023
2025
Board members and other officers (14)

Former names

  • Therapeutics Acquisition Corp.May 14, 2020 to Jun 30, 20212

Timeline

  1. Dec 27, 20238-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer24
  2. Oct 3, 20238-K Entered a material agreement; Other events25
  3. Aug 14, 20238-K Results of operations26
  4. Aug 3, 20238-K Change of auditor27
  5. Jun 13, 20238-K Executive or director change28
  6. Jun 5, 20238-K Shareholder vote29
  7. Feb 7, 20238-K Entered a material agreement30
  8. Sep 14, 20228-K Entered a material agreement; Other events31
  9. Sep 13, 20228-K Other events32
  10. Sep 12, 20228-K Regulation FD disclosure33
  11. Sep 6, 20228-K Regulation FD disclosure34
  12. Jun 3, 20228-K Shareholder vote35
  13. Jun 30, 2021New chief executive Joe A. McCann becomes CEO8
  14. Jul 7, 2020New chief executive Peter Kolchinsky becomes CEO9

Calendar

When it reported results

  1. Aug 14, 2023Reported quarterly or annual results26
  2. Mar 25, 2022Reported quarterly or annual results36

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

148 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 20 major events, 55 insider forms, 20 large holders, 44 other. The latest 20:

  1. Jan 8, 202415-12G EDGAR
  2. Dec 29, 2023EFFECT EDGAR
  3. Dec 29, 2023EFFECT EDGAR
  4. Dec 27, 2023POS AM EDGAR
  5. Dec 27, 2023POS AM EDGAR
  6. Dec 27, 2023S-8 POS EDGAR
  7. Dec 27, 2023S-8 POS EDGAR
  8. Dec 27, 2023S-8 POS EDGAR
  9. Dec 27, 20238-K EDGAR
  10. Dec 27, 20234 OWNERSHIP DOCUMENT EDGAR
  11. Dec 27, 20234 OWNERSHIP DOCUMENT EDGAR
  12. Dec 27, 20234 OWNERSHIP DOCUMENT EDGAR
  13. Dec 27, 20234 OWNERSHIP DOCUMENT EDGAR
  14. Dec 27, 20234 OWNERSHIP DOCUMENT EDGAR
  15. Dec 27, 20234 OWNERSHIP DOCUMENT EDGAR
  16. Dec 27, 20234 OWNERSHIP DOCUMENT EDGAR
  17. Dec 27, 20234 OWNERSHIP DOCUMENT EDGAR
  18. Dec 27, 20234 OWNERSHIP DOCUMENT EDGAR
  19. Dec 27, 20234 OWNERSHIP DOCUMENT EDGAR
  20. Dec 27, 20234 OWNERSHIP DOCUMENT EDGAR

The 148 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

10 open-market trades by officers, directors and large owners since October 2021: 8 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 18, 2023BVF INC/ILSale17,161,278$12.45$213.7MForm 4
Nov 29, 2022MCCANN JOE A.Chief Executive OfficerBuy2,160$6.64$14.3KForm 4
Nov 28, 2022Malik RajeshDirectorBuy3,700$6.66$24.6KForm 4
Nov 25, 2022HOGUE GERALD L.DirectorBuy3,660$6.82$25.0KForm 4
Nov 23, 2022Lubner David CharlesDirectorBuy3,600$6.85$24.7KForm 4
Nov 21, 2022MARGOLIN YAELDirectorBuy1,710$6.56$11.2KForm 4
Nov 18, 2022GOODMAN JONATHAN R.DirectorBuy6,000$6.33$38.0KForm 4
Nov 18, 2022SILBER ALLAN CExecutive ChairmanBuy22,397$6.50$145.6KForm 4
Nov 17, 2022SILBER ALLAN CExecutive ChairmanBuy27,603$6.00$165.6KForm 4
May 25, 2022FLESHNER NEIL E.Chief Medical OfficerSale564,204$7.51$4.2MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How POINT Biopharma Global Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPOINT Biopharma Global Inc.1
  • CIK0001811764
  • Employer ID (EIN)85-08004931
  • Filer status<br>emerging growth company1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4850 West 78Th Street, Indianapolis, IN 462681
  • Phone(317) 543-99571
  • Shares outstanding106,569,231 as of Nov 8, 20236
  • Public float$504.0M as of Jun 30, 20223
  • On EDGAR sinceMay 14, 20201
  • Filings285 in all: 4 (71), 8-K (34), 3 (21), CORRESP (15), 424B3 (14), SC 13G (14), SC 13G/A (12), 10-Q (11)1
    All 43 form types

    EFFECT (8), SC 13D/A (8), SC 14D9/A (8), SC TO-T/A (7), UPLOAD (7), 425 (6), POS AM (4), 10-K (3), S-1/A (3), S-4/A (3), S-8 (3), S-8 POS (3), SC 13D (3), 424B5 (2), DEF 14A (2), S-1 (2), SC14D9C (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 4/A (1), 424B4 (1), 5 (1), 5/A (1), 8-A12B (1), 8-K/A (1), ARS (1), CERT (1), DRS (1), S-1MEF (1), S-3 (1), S-4 (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2023
    Quarterly report (10-Q) Nov 13, 2023
    Proxy statement (DEF 14A) Apr 27, 2023
    Latest 8-K (8-K) Dec 27, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49